Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Bought by Olstein Capital Management L.P.

Olstein Capital Management L.P. lifted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 37.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 155,000 shares of the life sciences company’s stock after acquiring an additional 42,000 shares during the period. Olstein Capital Management L.P. owned 0.20% of Integra LifeSciences worth $2,816,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in IART. Principal Financial Group Inc. lifted its position in shares of Integra LifeSciences by 18.7% in the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock valued at $7,294,000 after acquiring an additional 63,266 shares in the last quarter. New York State Teachers Retirement System lifted its position in shares of Integra LifeSciences by 3.0% in the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock valued at $1,637,000 after acquiring an additional 2,616 shares in the last quarter. State of Alaska Department of Revenue lifted its position in shares of Integra LifeSciences by 144.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company’s stock valued at $2,393,000 after acquiring an additional 77,825 shares in the last quarter. Tandem Capital Management Corp ADV lifted its position in shares of Integra LifeSciences by 43.4% in the 3rd quarter. Tandem Capital Management Corp ADV now owns 38,851 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 11,765 shares in the last quarter. Finally, Northwest Investment Counselors LLC acquired a new position in Integra LifeSciences in the 3rd quarter valued at approximately $73,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 2.4 %

Shares of IART traded down $0.63 during mid-day trading on Thursday, hitting $26.07. 46,938 shares of the company’s stock were exchanged, compared to its average volume of 1,099,994. The firm has a fifty day moving average of $18.90 and a two-hundred day moving average of $24.40. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -296.67, a P/E/G ratio of 0.82 and a beta of 1.08. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.25%. The business had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period last year, the business posted $0.76 EPS. Integra LifeSciences’s revenue was down .4% compared to the same quarter last year. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IART. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. JMP Securities dropped their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Morgan Stanley upped their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Finally, Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average target price of $27.25.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.